Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers

Gastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these...

Full description

Bibliographic Details
Main Authors: Zhihao Lu, Zhi Peng, Chang Liu, Zhenghang Wang, Yakun Wang, Xi Jiao, Jian Li, Lin Shen
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:The Innovation
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666675820300412
id doaj-bdbdb47360f5403bb48d34c168d4940d
record_format Article
spelling doaj-bdbdb47360f5403bb48d34c168d4940d2021-02-07T04:25:51ZengElsevierThe Innovation2666-67582020-08-0112100041Current Status and Future Perspective of Immunotherapy in Gastrointestinal CancersZhihao Lu0Zhi Peng1Chang Liu2Zhenghang Wang3Yakun Wang4Xi Jiao5Jian Li6Lin Shen7Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, China; Corresponding authorDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 FuCheng Road, Hai-Dian District, Beijing, 100142, China; Corresponding authorGastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these patients remains poor. Recently, immunotherapy, involving programmed cell death-1 (PD-1) and its ligand (PD-L1), has shown promising efficacy in several solid cancers and seems to have become a potential treatment option for GI cancers This review focuses on data on the development of immunotherapy-based clinical trials in esophageal cancer, gastric cancer, and colorectal cancer. The predictive biomarkers and combination strategies in clinical trials and translational medicine are also discussed. Finally, prospects for immunotherapy in the treatment of GI cancers are described. Although only a small proportion of patients with GI cancers respond to PD-1/PD-L1 blockade, we strongly believe that precision immunotherapy might improve the overall survival of many more GI cancer patients in the future.http://www.sciencedirect.com/science/article/pii/S2666675820300412gastrointestinal cancerimmune checkpoint blockadebiomarkersprecision immunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Zhihao Lu
Zhi Peng
Chang Liu
Zhenghang Wang
Yakun Wang
Xi Jiao
Jian Li
Lin Shen
spellingShingle Zhihao Lu
Zhi Peng
Chang Liu
Zhenghang Wang
Yakun Wang
Xi Jiao
Jian Li
Lin Shen
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
The Innovation
gastrointestinal cancer
immune checkpoint blockade
biomarkers
precision immunotherapy
author_facet Zhihao Lu
Zhi Peng
Chang Liu
Zhenghang Wang
Yakun Wang
Xi Jiao
Jian Li
Lin Shen
author_sort Zhihao Lu
title Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
title_short Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
title_full Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
title_fullStr Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
title_full_unstemmed Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
title_sort current status and future perspective of immunotherapy in gastrointestinal cancers
publisher Elsevier
series The Innovation
issn 2666-6758
publishDate 2020-08-01
description Gastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these patients remains poor. Recently, immunotherapy, involving programmed cell death-1 (PD-1) and its ligand (PD-L1), has shown promising efficacy in several solid cancers and seems to have become a potential treatment option for GI cancers This review focuses on data on the development of immunotherapy-based clinical trials in esophageal cancer, gastric cancer, and colorectal cancer. The predictive biomarkers and combination strategies in clinical trials and translational medicine are also discussed. Finally, prospects for immunotherapy in the treatment of GI cancers are described. Although only a small proportion of patients with GI cancers respond to PD-1/PD-L1 blockade, we strongly believe that precision immunotherapy might improve the overall survival of many more GI cancer patients in the future.
topic gastrointestinal cancer
immune checkpoint blockade
biomarkers
precision immunotherapy
url http://www.sciencedirect.com/science/article/pii/S2666675820300412
work_keys_str_mv AT zhihaolu currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers
AT zhipeng currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers
AT changliu currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers
AT zhenghangwang currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers
AT yakunwang currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers
AT xijiao currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers
AT jianli currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers
AT linshen currentstatusandfutureperspectiveofimmunotherapyingastrointestinalcancers
_version_ 1724281950150066176